The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE

Lucia Lisi, Pierluigi Navarra, Cinzia Dello Russo, Susan Mcguire, Anthony Sharp, Gabriela Chiosis, Douglas L. Feinstein

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

6 Citazioni (Scopus)

Abstract

Ansamycins are very effective HSP90 inhibitors that showed significant beneficial effects in the treatment of EAE. However, their toxicity and poor stability in solution limit their clinical use. In the present study we have characterized the anti-inflammatory properties of a novel HSP90 inhibitor, PU-H71, and tested its effects in EAE. Our findings show that PU-H71 reduced lipopolysaccharide astrocyte activation but failed to reduce the inflammatory cytokine activation. In contrast to ansamycins, PU-H71 weakly affects EAE clinical course. In conclusion, although PU-H71 displayed some anti-inflammatory properties, it appeared in vivo less effective than the more toxic HSP90 inhibitors.
Lingua originaleEnglish
pagine (da-a)1-7
Numero di pagine7
RivistaJournal of Neuroimmunology
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • EAE
  • Glial activation
  • HSP90 inhibitors
  • PU-H71
  • astrocytes
  • microglia

Fingerprint Entra nei temi di ricerca di 'The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE'. Insieme formano una fingerprint unica.

Cita questo